医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Q2 & H1 FY20 Financial Results

2019年11月01日 PM05:29
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards (IFRS).

Q2 Performance Summary

H1 Performance Summary

 

Rs. 4,801 Cr
Revenue
[Up: 25% QoQ; 26% YoY]

Rs. 8,644 Cr
Revenue
[Up: 15% YoY]

 

57.5%
Gross Margin
[Q1 FY20: 51.7%; Q2 FY19: 55.0%]

54.9%
Gross Margin
[H1 FY19: 55.4%]

 

Rs.1,678 Cr
SGNA expenses
[Up: 39% QoQ, 36% YoY]

Rs. 2,884 Cr
SGNA expenses
[Up: 18% YoY]

 

Rs. 366 Cr
R&D expenses
[7.6% of Revenues]

Rs. 727 Cr
R&D expenses
[8.4% of Revenues]

 

Rs. 766 Cr
Profit before Tax
[Down: 10% QoQ; Up: 33% YoY]

Rs. 1,616 Cr
Profit before Tax
[Up: 50% YoY]

Commenting on the results, Co-Chairman and MD, GV Prasad said, “I am pleased with our performance across the businesses and strong cash generation during the quarter. We are progressing well in execution of our strategy and in our transformation journey on quality and efficiency.”

All amounts in millions, except EPS All US dollar amounts based on convenience translation rate of I USD = Rs. 70.64

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement

 

Particulars

Q2 FY20

Q2 FY19

YoY
Gr %

Q1 FY20

QoQ
Gr%

($)

(Rs.)

($)

(Rs.)

($)

(Rs.)

Revenues

680

48,009

538

37,978

26

544

38,435

25

Cost of Revenues

289

20,389

242

17,081

19

263

18,576

10

Gross Profit

391

27,620

296

20,897

32

281

19,859

39

Operating Expenses

 

 

 

 

 

 

 

 

Selling, General & Administrative expenses

238

16,777

175

12,372

36

171

12,065

39

Research and Development expenses

52

3,662

58

4,120

(11)

51

3,609

1

Other operating (income)

-2

-135

-9

-641

(79)

-53

-3,759

(96)

Results from operating activities

104

7,316

71

5,046

45

112

7,944

(8)

Net finance (income)

-3

-231

-9

-625

(63)

-6

-393

(41)

Share of (profit) / loss of equity accounted investees

-2

-117

-2

-109

8

-2

-163

(28)

Profit before income tax

108

7,664

82

5,780

33

120

8,500

(10)

Income tax expense / (benefit)

-46

-3,261

11

742

(539)

26

1,872

(274)

Profit for the period

155

10,925

71

5,038

117

94

6,628

65

 

 

 

 

 

 

 

 

 

Diluted Earnings Per Share (EPS)

0.93

65.82

0.43

30.31

117

0.57

39.91

65

As % to Revenues

Q2
FY20

 

 

Q2
FY19

 

 

 

 

Q1
FY20

Gross Profit

57.5

 

 

55.0

 

 

 

 

51.7

SG&A

34.9

 

 

32.6

 

 

 

 

31.4

R&D

7.6

 

 

10.8

 

 

 

 

9.4

EBITDA

 

29.9

 

 

22.8

 

 

 

 

29.5

PBT

16.0

 

 

15.2

 

 

 

 

22.1

PAT

22.8

 

 

13.3

 

 

 

 

17.2

EBITDA Computation

 

Particulars

Q2 FY20

 

 

 

Q2 FY19

 

 

 

Q1 FY20

($)

(Rs.)

 

 

 

($)

(Rs.)

 

 

 

($)

(Rs.)

Profit before Income Tax

108

7,664

 

 

 

82

5,780

 

 

 

120

8,500

Interest (income) net*

-3

(226)

 

 

 

(2)

(132)

 

 

 

(3)

(239)

Depreciation

33

2,306

 

 

 

29

2,033

 

 

 

30

2,124

Amortization

15

1,033

 

 

 

14

965

 

 

 

14

959

Impairment

50

3,561

 

 

 

 

 

 

(0)

(1)

EBITDA

203

14,338

 

 

 

122

8,646

 

 

 

161

11,343

* Includes income from Investments

Key Balance Sheet Items

 

Particulars

As on 30th Sep
2019

As on 30th June
2019

As on 30th Sep
2018

($)

(Rs.)

($)

(Rs.)

($)

(Rs.)

Cash and cash equivalents and other investments

431

30,446

403

28,439

295

20,837

Trade receivables (current & non-current)

597

42,153

537

37,961

656

46,317

Inventories

496

35,033

497

35,137

460

32,490

Property, plant and equipment

750

53,008

766

54,083

802

56,640

Goodwill and Other Intangible assets

628

44,340

677

47,821

726

51,290

Loans and borrowings (current & non-current)

447

31,545

487

34,387

786

55,522

Trade payables

218

15,434

210

14,842

199

14,073

Equity

2,177

1,53,816

2,070

1,46,208

1,861

1,31,446

Revenue Mix by Segment

 

Particulars

Q2 FY20

Q2 FY19

YoY
Growth %

Q1 FY20

QoQ
Growth %

(Rs.)

(Rs.)

(Rs.)

Global Generics

32,816

30,536

7%

32,982

-1%

North America

14,265

14,265

0%

16,322

-13%

Europe

2,764

1,915

<p class="bwcellpma

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders
  • 武田薬品とニューヨーク科学アカデミーが2020年Innovators in Science Awardの受賞者を発表
  • 新证据显示,森永乳业的益生菌短双歧杆菌A1可改善认知功能障碍老年患者的记忆力
  • 实验室研究证实BETADINE®消毒产品对COVID-19病毒有效
  • 国際WELLビルディング協会がCOVID-19を受けてのWELL健康・安全評定への登録を開始、多くの組織による早期採用を見る